

West Virginia Medicaid Drug Utilization Review Board Minutes November 16, 2011

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair
David Gloss, MD, Vice Chair
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Michael Ballow, PharmD
Mary Nemeth-Pyles, MSN, RN, CS

Members Absent:

K.C. Lovin, PA-C
Ernest Miller, DO
C.K. Babcock, PharmD

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services
Priya Shah, PharmD, Drug Utilization Review Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Data Analyst
Hyla Harvey, MD, Medical Director

Contract Staff:

Chris Hale, PharmD, Rational Drug Therapy Program (RDTP)
Kim Broedel-Zaugg, RPh, PhD, Marshall University
Rob Stanton, PharmD, MBA, Marshall University
Jon Willis, Marshall University
Eric Sears, RPh, Gainwell
Joe Bergondo, PharmD, Change Healthcare

- I. **INTRODUCTIONS**
 - a. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:03 pm EDT. The DUR Board and others introduced themselves.

- II. **ARRPOVAL OF MINUTES FROM May 25, 2022 DUR BOARD MEETING**
 - a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

- III. **OLD BUSINESS**

IV. **NEW BUSINESS**

a. **Speakers**

- i. None

b. **Updates from October 26, 2022 P & T Committee Meeting.**

c. **Proposed Prior Authorization Criteria:** Attachment A

- i. **Lyvispah/Fleqsuvy/oral baclofen solution:** approved as presented
- ii. **Myfembree/Oriahnn/Orillissa:** approved as presented
- iii. **Fintepla:** approved as amended
- iv. **Dupixent:** approved as amended
- v. **Kesimpta:** approved as amended
- vi. **Belsomra:** approved as amended
- vii. **IBS agents-Osmotic laxative requirement removal:** approved as presented

V. **REPORTS –3rd Quarter 2022**

- a. **Gainwell Technologies Quarterly Report:** Mr. Sears presented an overview of the 2022 Third Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Hale presented a review of the prior authorization program for the Third Quarter of 2022. Attachment C.
- c. **Marshall University:** Dr. Stanton presented a review of the RDUR Third Quarter of 2022 activities. Attachment D.

VI. **OTHER BUSINESS**

VII. **NEXT MEETING AND ADJOURNMENT**

- VIII. a. The meeting concluded at 5:30 pm EDT.
- b. The next meeting will be February 15, 2023 from 4-6pm on virtual platform.